Skip to content

Macquarie gives #39;outperform#39; rating to Mankind Pharma, sees 30% upside

Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.

Read More

​ Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share. Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.  Moneycontrol Latest News Read More  

Leave a Reply

Generated by Feedzy
en_USEnglish
%d bloggers like this: